Makena Might Stay On Market Despite Failed Confirmatory Trial In Pre-Term Birth

Subgroup analyses by AMAG may support ongoing use, but the once-controversial Makena seems unlikely to be pulled from the US market in any event since compounded progesterone is the only alternative therapy.

Pregnant belly

AMAG Pharmaceuticals Inc.'s Makena (hydroxyprogesterone caproate injection) failed to achieve both co-primary endpoints in the PROLONG confirmatory study required by the US FDA when it granted the product accelerated approval in 2011, but that doesn't necessarily mean the pre-term birth drug will need to be withdrawn.

While PROLONG was meant to confirm FDA's accelerated approval decision for Makena, it's unclear whether the agency will require AMAG...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards